Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec?)

摘要

Imatinib mesylate (Gleevec?, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea -like drug eruptions are rare. Here, we report a case of pityriasis rosea -like drug eruption that developed following the administration of imatinib mesylate to treat CML.